US 2014/0371237 A1Published application

p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth

OwnerJörn Bullerdiek, Dominique N. Markowskiinventors

Life of this patent

Estimating the term…

Abstract

Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.

Claims14

Dependent claims

A method of treating a subject having uterine leiomyoma (UL), comprising administering an MDM2 inhibitor selected from nutlins in a therapeutically effective amount to a patient in need thereof.

Dependencies are inferred from the claim text.

Facts

Application: 14/453,090Filed 6 Aug 2014
Priority: EP 10 001 307.79 Feb 2010
Published: 18 Dec 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification26 codes

A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/167
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the nitrogen of a carboxamide group directly attached to the aromatic ring,…
A61K 31/17
Amides, e.g. hydroxamic acids: having the group >N—C—N< or >N—C—N<, e.g. urea, thiourea, carmustine

Family

Application13/578,010Division · filed 31 Oct 2012
Application14/453,090Division
US 2013/0149314 A1Published application
US 2014/0371237 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results